- Home
- C vs SNY Comparison
C vs SNY Comparison
Compare C & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- C
- SNY
- Stock Information
- Founded
- C 1812
- SNY 1994
- Country
- C United States
- SNY France
- Employees
- C N/A
- SNY N/A
- Industry
- C Major Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- C Finance
- SNY Health Care
- Exchange
- C Nasdaq
- SNY Nasdaq
- Market Cap
- C 127.5B
- SNY 144.8B
- IPO Year
- C N/A
- SNY N/A
- Fundamental
- Price
- C $73.99
- SNY $55.47
- Analyst Decision
- C Buy
- SNY Buy
- Analyst Count
- C 14
- SNY 2
- Target Price
- C $86.71
- SNY $62.50
- AVG Volume (30 Days)
- C 16.9M
- SNY 3.0M
- Earning Date
- C 04-15-2025
- SNY 04-24-2025
- Dividend Yield
- C 3.01%
- SNY 3.96%
- EPS Growth
- C 47.03
- SNY 2.94
- EPS
- C 5.94
- SNY 4.60
- Revenue
- C $71,363,000,000.00
- SNY $45,849,466,833.00
- Revenue This Year
- C $20.06
- SNY $6.91
- Revenue Next Year
- C $3.69
- SNY $6.60
- P/E Ratio
- C $12.53
- SNY $12.06
- Revenue Growth
- C 0.94
- SNY 7.73
- 52 Week Low
- C $53.51
- SNY $45.22
- 52 Week High
- C $84.74
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- C 53.05
- SNY 50.38
- Support Level
- C $66.73
- SNY $55.78
- Resistance Level
- C $72.98
- SNY $59.17
- Average True Range (ATR)
- C 1.95
- SNY 0.78
- MACD
- C 0.67
- SNY -0.43
- Stochastic Oscillator
- C 95.54
- SNY 20.12
About C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.